Related Experiment Video
Updated: Jul 4, 2026
03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable
P-M Llorca1, P Bouhours, V Moreau-Mallet
1Centre hospitalier universitaire, psychiatrie B, place Henri-Dunand, 63003 Clermont-Ferrand cedex 1, France. pmllorca@chu-clermontferrand.fr
L'Encephale
|July 4, 2008
Summary
Directly initiating long-acting injectable risperidone (LAIR) improved symptoms and functioning in adults with psychotic disorders. This treatment option enhanced quality of life and reduced movement disorders effectively.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Schizophrenia and related psychotic disorders require effective long-term management.
- Treatment changes are often necessary for patients with psychotic disorders.
- Long-acting injectable antipsychotics offer potential benefits for adherence and symptom control.
Purpose of the Study:
- To evaluate the efficacy and tolerability of directly initiating long-acting injectable risperidone (LAIR).
- To assess LAIR's impact on symptom severity, functioning, quality of life, and patient satisfaction in adults with psychotic disorders.
- To determine if LAIR is a viable treatment option for patients needing a change in medication.
Main Methods:
- A prospective study involving 202 adult patients with schizophrenia or other psychotic disorders.
- Patients received direct initiation of 25 mg LAIR every 14 days, with potential dose increases to 37.5 or 50 mg.
- Treatment duration was six months, with assessments of efficacy and tolerability.
Main Results:
- Significant reductions in Positive and Negative Syndrome Scale (PANSS) scores were observed from baseline to endpoint.
- Improvements were noted in Clinical Global Impression-Disease Severity (CGI-S), Global Assessment of Functioning (GAF), and SF-36 quality of life scores.
- Significant reductions in extrapyramidal symptoms (ESRS) and Parkinsonism subscale scores were reported, alongside increased patient satisfaction.
Conclusions:
- Direct initiation of LAIR is an effective treatment for adults with psychotic disorders.
- LAIR significantly improves disease symptoms, patient functioning, and movement disorders.
- LAIR offers a valuable option for managing psychotic disorders, enhancing quality of life and treatment satisfaction.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...